Philippe Constantin Wiesel - 18 Mar 2026 Form 3 Insider Report for Agomab Therapeutics NV (AGMB)

Role
Chief Medical Officer
Signature
/s/ Ellen Lefever, Attorney-in-Fact
Issuer symbol
AGMB
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 16:01:30 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wiesel Philippe Constantin Chief Medical Officer AGOMAB THERAPEUTICS NV, POSTHOFLEI 1/6, ANTWERPEN, BELGIUM /s/ Ellen Lefever, Attorney-in-Fact 18 Mar 2026 0002120884

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 21,732 $1.13 Direct F1, F2, F3
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 15,000 $1.13 Direct F1, F2, F3
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 11,992 $1.13 Direct F1, F2, F3
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 23,983 $1.13 Direct F1, F2, F3
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 155,433 $0.000500 Direct F1, F2, F3
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 30,520 $0.000500 Direct F1, F2, F3
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 87,641 $0.000500 Direct F1, F2, F3
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 6,927 $2.81 Direct F2, F3, F4
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 140,758 $3.42 Direct F2, F3, F4
holding AGMB Stock Option (Right to Buy) 18 Mar 2026 Common shares 133,789 $14.26 Direct F2, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option are fully vested and exercisable.
F2 The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F3 The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
F4 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F5 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney